GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Beneish M-Score

Aytu BioPharma (Aytu BioPharma) Beneish M-Score : -2.85 (As of Apr. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aytu BioPharma's Beneish M-Score or its related term are showing as below:

AYTU' s Beneish M-Score Range Over the Past 10 Years
Min: -13.93   Med: -2.42   Max: 1608.54
Current: -2.85

During the past 13 years, the highest Beneish M-Score of Aytu BioPharma was 1608.54. The lowest was -13.93. And the median was -2.42.


Aytu BioPharma Beneish M-Score Historical Data

The historical data trend for Aytu BioPharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Beneish M-Score Chart

Aytu BioPharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.63 0.13 -0.35 -2.99 -2.59

Aytu BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.46 -2.59 -3.07 -2.85

Competitive Comparison of Aytu BioPharma's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Beneish M-Score falls into.



Aytu BioPharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aytu BioPharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2337+0.528 * 0.9413+0.404 * 0.9272+0.892 * 0.9329+0.115 * 0.8924
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9161+4.679 * -0.095726-0.327 * 1.0444
=-2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $29.40 Mil.
Revenue was 22.934 + 22.099 + 30.732 + 22.733 = $98.50 Mil.
Gross Profit was 16.203 + 14.784 + 18.564 + 12.743 = $62.29 Mil.
Total Current Assets was $71.37 Mil.
Total Assets was $131.25 Mil.
Property, Plant and Equipment(Net PPE) was $3.26 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.72 Mil.
Selling, General, & Admin. Expense(SGA) was $60.47 Mil.
Total Current Liabilities was $64.19 Mil.
Long-Term Debt & Capital Lease Obligation was $14.98 Mil.
Net Income was -0.22 + -8.12 + -2.457 + -7.2 = $-18.00 Mil.
Non Operating Income was -1.756 + -6.616 + -5.266 + 2.092 = $-11.55 Mil.
Cash Flow from Operations was -0.135 + -0.211 + 9.365 + -2.906 = $6.11 Mil.
Total Receivables was $25.55 Mil.
Revenue was 26.279 + 27.655 + 27.448 + 24.199 = $105.58 Mil.
Gross Profit was 17.293 + 18.032 + 14.842 + 12.686 = $62.85 Mil.
Total Current Assets was $70.61 Mil.
Total Assets was $141.44 Mil.
Property, Plant and Equipment(Net PPE) was $5.02 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.30 Mil.
Selling, General, & Admin. Expense(SGA) was $70.76 Mil.
Total Current Liabilities was $67.15 Mil.
Long-Term Debt & Capital Lease Obligation was $14.53 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(29.403 / 98.498) / (25.547 / 105.581)
=0.298514 / 0.241966
=1.2337

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(62.853 / 105.581) / (62.294 / 98.498)
=0.595306 / 0.632439
=0.9413

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (71.371 + 3.26) / 131.249) / (1 - (70.611 + 5.019) / 141.436)
=0.431379 / 0.465271
=0.9272

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=98.498 / 105.581
=0.9329

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.301 / (9.301 + 5.019)) / (8.717 / (8.717 + 3.26))
=0.649511 / 0.727812
=0.8924

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(60.469 / 98.498) / (70.756 / 105.581)
=0.613911 / 0.670158
=0.9161

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((14.978 + 64.187) / 131.249) / ((14.533 + 67.15) / 141.436)
=0.603167 / 0.577526
=1.0444

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-17.997 - -11.546 - 6.113) / 131.249
=-0.095726

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aytu BioPharma has a M-score of -2.85 suggests that the company is unlikely to be a manipulator.


Aytu BioPharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma (Aytu BioPharma) Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Executives
Christopher Brooke officer: Chief Operating Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow officer: Chief Business Officer 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio director C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery director P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu director
Mark K Oki officer: Chief Financial Officer C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow director, officer: Chief Executive Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain director C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka officer: Chief Commerical Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050